Summary: Seven hundred and four HIV-1/2-positive, antiretroviral therapy (ART) naïve patients were screened for HTLV-1 infection. Antibodies to HTLV-1 were found in 32/704 (4.5%) of the patients. Each co-infected individual was matched with two HIV mono-infected patients according to World Health Organization clinical stage, age +5 years and gender. Key clinical and laboratory characteristics were compared between the two groups. Mono-infected and co-infected patients displayed similar clinical characteristics. However, co-infected patients had higher absolute CD4þ T-cell counts (P ¼ 0.001), higher percentage CD4þ T-cell counts (P , 0.001) and higher CD4/CD8 ratios (P , 0.001). Although HIV plasma RNA viral loads were inversely correlated with CD4þ T-cell-counts in mono-infected patients (P , 0.0001), a correlation was not found in co-infected individuals (P ¼ 0.11). Patients with untreated HIV and HTLV-1 co-infection show a dissociation between immunological and HIV virological markers. Current recommendations for initiating ART and chemoprophylaxis against opportunistic infections in resource-poor settings rely on more readily available CD4þ T-cell counts without viral load parameters. These guidelines are not appropriate for co-infected individuals in whom high CD4þ T-cell counts persist despite high HIV viral load states. Thus, for co-infected patients, even in resource-poor settings, HIV viral loads are likely to contribute information crucial for the appropriate timing of ART introduction.
INTRODUCTION
Human T-cell lymphotropic virus type 1 (HTLV-1) and human immunodeficiency virus type 1/2 (HIV-1/2) are genetically and functionally distinct retroviruses that target CD4þ T lymphocytes through different surface receptors. HTLV-1 is frequently associated with lymphocytosis, although malignant transformation of infected cells, producing acute or chronic T-cell leukaemia/lymphoma, is much less common. 1 In contrast, HIV infection causes shortened survival time and impaired production of CD4þ T-cells, with a progressive decline of this cell population in the peripheral blood. 2 More than 50% of the global HIV-infected population, and around 72% (or 4.7 million) of individuals in need of antiretroviral (ARV) therapy live in sub-Saharan Africa, a region that also bears a significant burden of HTLV-1 infection. 3, 4 In 2007, only one in four people in need of treatment in this region was on ARV therapy. 3 In Mozambique, a country with 19 million inhabitants, the prevalence of HIV infection in adults is estimated to be 16.0%. In October 2008, an estimated 489,000 patients were being followed in HIV outpatient clinics in Mozambique. Of the 430,000 people who were in need of ARV drugs throughout the country, only about 121,000 were initiated on this therapy by October 2008 (Source of Information: Medical Assistance Department, Ministry of Health, Mozambique). ARV therapy initiation in Mozambique is primarily guided by the CD4þ T-cell count and by the HIV clinical stage on the basis that CD4þ T-cell count is considered to be a reliable and available parameter to guide decision-making during management of HIV infection, 5, 6 whereas HIV viral load monitoring is generally unavailable throughout the country.
The basis of the heterogeneous geographical and demographic distribution of HTLV-1 in Africa is not well understood. In southern and central Africa, the prevalence of HTLV-1 infection has been reported to range between 0.5% and 7.1%, 7 -13 peaking in groups reporting high rates of sexual activity and in HIV-infected individuals, 14 -19 and in this population sexual transmission of HTLV-1 is thought to be a dominant mode of acquisition. With the HIV/AIDS epidemic on the rise, it is foreseeable that individuals co-infected with HIV and HTLV-1 will be frequently seen at HIV treatment and care centres.
Despite the high prevalence of both viruses in sub-Saharan Africa, little data are available about the clinical presentation of co-infected individuals in the region. Studies in other regions, including South American, show that in co-infected patients clinical progression of HIV infection occurs despite normal or high CD4þ T-cell counts. 20 -22 These apparently paradoxical findings are of a even greater relevance in the context of the scaling-up of ARV therapy programmes throughout sub-Saharan Africa as CD4 cell levels are the dominant criterion for timing institution of antiretroviral therapy (ART). Against this background, we investigated the clinical and laboratory characteristics of HIV-infected patients with HTLV-1 co-infection in Maputo, Mozambique.
METHODS

Study design
A nested case-control study was designed to enrol HIV positive patients presenting to an HIV Outpatient Clinic (HOP) for their clinical assessment after an HIV screening test. HIV-positive patients co-infected with HTLV-1 (co-infected patients) were defined as cases and HIV-positive patients without co-infection with HTLV-1 (mono-infected patients) were considered to be controls allowing assessment of the impact of HTLV-1 superimposed on HIV-1 infection.
This study was approved by the National Health Bioethics Committee in Mozambique and by the Sydney University Ethics Committee, Australia. The Sydney South West Area Health Service Ethics Research Committee (RPAH Zone) was also notified and endorsed the study.
Subjects
All subjects for the study were recruited from an ongoing cohort of HIV-infected individuals at the HOP within the Alto Maé Health Centre in Maputo City, Mozambique. Patients are referred to this HOP from a voluntary counselling and testing (VCT) service located within the same Health Centre. This VCT service is one of many institutions offering free of charge HIV diagnosis for the public in Maputo City.
Informed consent to participate in the study was requested from all consecutive patients coming to the HOP for routine HIV-related clinical care visits in the period between 13 March and 2 June 2006. Exclusion criteria were present or past history of ARV therapy, age less than 18 years, current pregnancy, and those who declined to participate or were unable to give informed consent.
Demographic, clinical and laboratory data
All consenting patients eligible for the study gave 5 mL of venous blood at the first visit. This specimen was used to determine HTLV-1 status. Two weeks after the first visit, patients returned to collect their HTLV-1 test result. At this time, each patient with a positive HTLV-1 result (case) was matched with two patients with negative HTLV-1 results (controls) for further study. The matching was performed based on World Health Organization (WHO) clinical staging system for HIV, age (+5 years) and gender. For cases for which there were more than two possible controls, the two closest in age to the case were selected. The selection of controls was made without prior knowledge of full blood counts or CD4þ T-cell counts results.
The researcher using a structured questionnaire then interviewed cases and controls. The questionnaire included: sociodemographic data, sexual/reproductive history and clinical data. General physical and neurological examination was performed in all patients enrolled to assess patient status by WHO clinical staging system for HIV and to stage HTLV-1 related diseases, specifically the presence of neurological manifestations 23 and skin lesions. To minimize the risk of recall bias caused by the clinical researcher's knowledge of HTLV-1 status, another medical doctor who was blinded to HTLV-1 status confirmed all neurological signs and symptoms or skin lesions. Agreement between the two doctors was taken as the definitive finding. Finally, an additional 7 mL of blood was drawn from both cases and controls to perform T-cell subsets and HIV-RNA viral load.
Laboratory assays
HIV serology
All patients enrolled in this study were tested for HIV 1/2 infection at the VCT services of the Health Centre. The national algorithm for HIV diagnosis using the sequential testing with two rapid assays was followed. All individuals were first screened using the Determine HIV-1/2 test (Abbott Laboratories, Tokyo, Japan). Individuals whose specimens were reactive on the screening assay were further tested using the Uni-Gold HIV test (Trinity Biotech, Ireland). We did not perform laboratory assays to discriminate infections with HIV-1 from those with HIV-2 as HIV-1 is known to cause more than 99% of HIV infections in Mozambique (Source of information: Ministry of Health, Mozambique).
HTLV serology
Blood samples were screened for HTLV-1 using an immunoenzymatic qualitative test, Murex HTLV-1 þ 2 (Murex Biotech Limited, Dartford, UK). Samples with reactive results were further tested using a Western blot, HTLV BLOT 2.4 (Genelabs w Diagnostics, Geneva, Switzerland). All patients reactive to antigens codified by the GAG gene (p19 with or without p24) and to two antigens encoded by the ENV gene (GD21 and rgp46-I) were considered as positive for HTLV-1.
T-cell subsets immunophenotyping
Immunophenotyping was performed on fresh whole blood using a FACSCalibur TM flow cytometer (Becton Dickinson, USA). MultiTEST reagents, TruCOUNT tubes and MultiTEST software (all from Becton Dickinson, California, USA) were used in a lyse-no wash protocol to determine absolute and percentage values for T-cell subsets (CD4þ T-cells, CD8þ T-cells and CD4þ T/CD8þ T ratio).
HIV-RNA viral load
Plasma samples were stored at 270ºC until viral load was assayed on a COBAS w TaqMan 48 analyser (Roche Diagnostics, Penzburg, Germany) for automated amplification and detection of nucleic acid. HIV-1 viral load was determined using the COBAS w TaqMan TM HIV-1 test, for use with the High Pure System (all from Roche Diagnostics, Germany). This assay can quantify HIV-1 RNA over a range of 40-10,000,000 copies/mL. 
Statistical analysis
RESULTS
Demographic characteristics and clinical history
From 724 HIV 1/2-infected patients invited to participate, 704 (97.4%) consented to be screened for HTLV-1 infection. HTLV-1 infection was identified in 32/704 patients (4.5%, 95% CI 3.0-6.0). Three patients with a positive HTLV-1 antibody test did not return to collect their result and were excluded from the study. Sexual history, clinical presentation and laboratory findings were compared between 29 HIV/HTLV-1 dually infected patients and 59 matched patients who were HIV-positive but HTLV-1 negative.
Co-infected and mono-infected patients were comparable with respect to demographic characteristics as well as sexual and reproductive history ( Table 1 The most common neurological manifestation in both groups was sensory symptoms (tingling, pins, needles and burning 
Clinical manifestations and HIV disease staging
Lymphocyte profiles
Co-infected patients had higher median of total leukocytes count, higher CD4þ T-cell (absolute/percent) count, lower CD8þ T-cell percent count and higher CD4þ T/CD8þ T ratio ( Table 3) 
HIV-1 viral load
The median HIV RNA viral load was 56,385 copies/mL (IQR 14,749-277,557) in co-infected patients compared with 37,573 copies/mL (IQR 11,322-176,837) in mono-infected patients (P ¼ 0.36). In both groups, the HIV-RNA load tended to increase with clinical progression of HIV infection (Figure 2 ). However, a statistically significant increase of HIV-RNA viral load by HIV clinical stage was only observed in patients with co-infection (P ¼ 0.04 versus P ¼ 0.10).
As expected, we documented a strong inverse relationship between levels of HIV-RNA and absolute CD4þ T-cell counts in mono-infected patients (95% CI 20.73 to 20.38, P , 0.0001). However, of importance, a similar relationship was not observed in patients with HIV/HTLV-1 co-infection (95% CI 20.60 to 0.07, P ¼ 0.11).
DISCUSSION
The prevalence of HTLV-1 infection is known to vary from region to region. However, in the same geographical region, it can vary in different population subgroups, probably reflecting the diverse modes of its transmission. 24 The overall prevalence of anti-HTLV-1 antibodies among HIV positive patients found ........................................................................................................................................ ..... in this study is markedly higher than previously reported in African blood donors. 9, 25, 26 This would be consistent with those subjects with HIV also being at increased behavioral risk for acquiring HTLV-1 infection as both viruses have the same routes of transmission. However, it could equally be consistent with widespread epidemics of HIV and HTLV-1 running in parallel but with different transmissibility parameters.
In some countries with a high prevalence of intravenous drug use (IDU), the prevalence of HTLV-1 infection is considerably higher. 27 In our study, we did not report any case of IDU. It has been estimated that 80 -90% of HIV infections in the developing world are due to heterosexual transmission. 28, 29 It is most likely that, in our setting, the major form of horizontal transmission of HTLV-1 is through heterosexual intercourse. However, it may also possible that the transmission of retroviruses through needles and surgical instruments at health facilities or at traditional healing practices play a relevant epidemiological role.
As already reported in other geographical regions and diverse populations, 19, 20, 22, 27, 30, 31 Mozambican patients co-infected with HTLV-1 displayed higher CD4þ T-cell counts when compared with mono-infected patients matched for clinical stage of HIV disease. We could not investigate the relationship between HTLV-1 infection and HIV disease progression in individual patients due to the cross-sectional design of our study.
Nevertheless, it was evident that BMI decreased with clinical progression of HIV infection in all patients. This suggests that HIV disease progression also leads to clinical deterioration of co-infected patients. In fact, BMI was generally lower in co-infected patients, although this was shown not to be statistically significant (P ¼ 0.06). We did not find any statistical difference comparing demographic, sexual and reproductive characteristics between cases and controls, which makes it less likely that the high CD4þ T-cell counts found in co-infected patients were biased by the difference in duration of HIV infection. Incidental to the primary goals of this study, we looked at clinical features in major organ systems but could not associate any neurological symptoms or skin lesions with HTLV-1 infection, probably due to the small number of patients enrolled in the study.
In southern Africa, patients showing CD4þ T lymphocyte counts that do not reflect their HIV clinical staging should be suspected as having HTLV-1 infection. In our study, 60.0% , in whom HAART can be started when HIV-RNA viral load levels indicate significant risk of progression. 23 This study suggests that HIV-RNA viral load increases markedly with clinical progression of HIV-HTLV co-infected patients (Figure 2) . Therefore, HIV-RNA viral load might give important additional information about the true risk of early progression to more advanced clinical stages in these patients. Additionally, HIV viral load is also likely to be a much more reliable guide to determining intervention points with ARV in HIV-HTLV co-infected subjects.
Our results support the hypothesis that, in HIV/HTLV-1 co-infected patients, the dissociation between clinical and immunological markers derive from a loss of the inverse correlation between the HIV viral load and the CD4þ T-cell count as a direct result of HTLV-1 infection. This study did not address the molecular basis of the protection of CD4 T-cells from rapid decline in association with HIV viraemia but it provides a strong rationale for such future studies. Our results are of particular relevance for care/treatment scale-up programmes in sub-Saharan Africa, where CD4þ T lymphocyte counts constitute the main laboratory parameter used for checking HIV disease progression as well as guiding HAART initiation and monitoring. The small number of our sample size, the absence of severe AIDS defining illnesses in the studied population and the low numbers of patients on WHO stage III of HIV infection constitute limitations of this study. These limitations, together with the cross-sectional nature of the study, did not allow us to define the impact of co-infection on HIV disease progression.
Despite its limitations, this study does not support the use in HTLV-1 co-infected patients of current recommendations for initiation of ART and chemoprophylaxis against opportunistic infections according to CD4þ T-cell counts. Thus, in settings with a high prevalence of HTLV-1 infection among the HIV-1 infected population, serological testing for HTLV-1 should ideally be available so that HIV viral load might be integrated into the treatment initiation algorithm. Defining appropriate thresholds of HIV viral load relevant to intervention points for co-infected patients will require longitudinal studies.
In the short term, it is unlikely that overburdened health systems in sub-Saharan Africa will be able to routinely test for HTLV-1 infection and/or HIV viral load. Therefore, in patients with dissociation between clinical and immunological parameters, the WHO clinical staging system, with minimal weight placed on CD4 T-cell data, should be recommended to monitor progression of HIV infection and guide initiation of therapy.
